synthetic vaccines

Summary

Summary: Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified.

Top Publications

  1. ncbi A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea
    Blaise Genton
    Papua New Guinea Institute of Medical Research, Maprik, Papua New Guinea
    J Infect Dis 185:820-7. 2002
  2. ncbi Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria
    Elissa M Malkin
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5640 Fishers Lane, Twinbrook 1, Room 1123, Rockville, MD 20852, USA
    Vaccine 23:3131-8. 2005
  3. ncbi Anti-tick vaccines
    P Willadsen
    CSIRO Livestock Industries, Queensland Bioscience Precinct, 306 Carmody Road, St Lucia, Queensland 4067, Australia
    Parasitology 129:S367-87. 2004
  4. pmc Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1
    Stephen Mark Tompkins
    Food and Drug Administration, Bethesda, Maryland, USA
    Emerg Infect Dis 13:426-35. 2007
  5. pmc Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon
    Katarina Radosevic
    Crucell Holland BV, Archimedesweg 4 6, 2333 CN Leiden, The Netherlands
    Infect Immun 75:4105-15. 2007
  6. ncbi Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma
    Fernando Abaitua
    Department of Molecular and Cellular Biology, Centro Nacional de Biotecnologia, CSIC, Campus Ciudad Universitaria Cantoblanco, 28049 Madrid, Spain
    Virus Res 116:11-20. 2006
  7. pmc Production of human papillomavirus type 16 virus-like particles in transgenic plants
    Sophia Biemelt
    Institut fur Pflanzengenetik und Kulturpflanzenforschung, 06466 Gatersleben, Germany
    J Virol 77:9211-20. 2003
  8. pmc Trafficking of antigen-specific CD8+ T lymphocytes to mucosal surfaces following intramuscular vaccination
    David R Kaufman
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    J Immunol 181:4188-98. 2008
  9. pmc Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer
    Kazutoyo Miura
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA
    Malar J 6:107. 2007
  10. ncbi Immunization with VP2 is sufficient for protection against lethal challenge with African horsesickness virus Type 4
    M A Stone-Marschat
    Molecular Pathology Unit, Plum Island Animal Disease Center, USDA, Greenport, New York 11944 0848, USA
    Virology 220:219-22. 1996

Research Grants

  1. Experimental Molecular Vaccines for Schistosomiasis
    Afzal A Siddiqui; Fiscal Year: 2012
  2. Synthesis of immunogenic glycolipopeptides for the development of vaccines for Ch
    Katja Michael; Fiscal Year: 2010
  3. A fully synthetic carbohydrate-based cancer vaccine
    Geert Jan Boons; Fiscal Year: 2013
  4. PHYSIOLOGICAL CHEMISTRY OF INTEGRIN FUNCTION
    MICHAEL LORAN DUSTIN; Fiscal Year: 2010
  5. Synthetic Ligands for Modulating B-Cell Responses
    Laura L Kiessling; Fiscal Year: 2013
  6. UC Davis/NIH NeuroMab Facility
    James S Trimmer; Fiscal Year: 2013
  7. Molecular Recognition in Dendrimers Based on Melamine
    Eric Simanek; Fiscal Year: 2009
  8. SBIR TOPIC 255
    PETER M PUSHKO; Fiscal Year: 2009
  9. CARHOHYDRATE MOIETIES OF GP120
    Khushi Matta; Fiscal Year: 1993
  10. T CELL IMMUNITY AND SYNTHETIC PEPTIDE AIDS VACCINES
    Amnon Altman; Fiscal Year: 1991

Detail Information

Publications317 found, 100 shown here

  1. ncbi A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea
    Blaise Genton
    Papua New Guinea Institute of Medical Research, Maprik, Papua New Guinea
    J Infect Dis 185:820-7. 2002
    ..The vaccine-induced selection pressure exerted on the parasites and its consequences for morbidity strongly argue for developing vaccines comprising conserved antigens and/or multiple components covering all important allelic types...
  2. ncbi Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria
    Elissa M Malkin
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5640 Fishers Lane, Twinbrook 1, Room 1123, Rockville, MD 20852, USA
    Vaccine 23:3131-8. 2005
    ..Pvs25H generates transmission blocking immunity in humans against P. vivax demonstrating the potential of this antigen as a component of a transmission blocking vaccine...
  3. ncbi Anti-tick vaccines
    P Willadsen
    CSIRO Livestock Industries, Queensland Bioscience Precinct, 306 Carmody Road, St Lucia, Queensland 4067, Australia
    Parasitology 129:S367-87. 2004
    ..The groundwork has been laid; the potential of the field is still to be effectively exploited...
  4. pmc Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1
    Stephen Mark Tompkins
    Food and Drug Administration, Bethesda, Maryland, USA
    Emerg Infect Dis 13:426-35. 2007
    ..This M2 prime-boost vaccination conferred broad protection against challenge with lethal influenza A, including an H5N1 strain. Vaccination with M2, with key sequences represented, may provide broad protection against influenza A...
  5. pmc Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon
    Katarina Radosevic
    Crucell Holland BV, Archimedesweg 4 6, 2333 CN Leiden, The Netherlands
    Infect Immun 75:4105-15. 2007
    ..These results unify conflicting reports on the relative importance of CD4 versus CD8 T-cell responses in protection and emphasize the key role of IFN-gamma...
  6. ncbi Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma
    Fernando Abaitua
    Department of Molecular and Cellular Biology, Centro Nacional de Biotecnologia, CSIC, Campus Ciudad Universitaria Cantoblanco, 28049 Madrid, Spain
    Virus Res 116:11-20. 2006
    ..The increment of the CD8+ T cell response was higher in a DNA/MVA prime/boost protocol. Thus, the immune response of MVA vectors can be improved with the co-delivery of the cytokines IFN-gamma or IL-12...
  7. pmc Production of human papillomavirus type 16 virus-like particles in transgenic plants
    Sophia Biemelt
    Institut fur Pflanzengenetik und Kulturpflanzenforschung, 06466 Gatersleben, Germany
    J Virol 77:9211-20. 2003
    ..Our data, however, indicate that an anti-L1 response was primed in about half of the 24 animals...
  8. pmc Trafficking of antigen-specific CD8+ T lymphocytes to mucosal surfaces following intramuscular vaccination
    David R Kaufman
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    J Immunol 181:4188-98. 2008
    ..Thus, i.m. vaccination can overcome immune compartmentalization and generate robust mucosal CD8(+) T lymphocyte memory. These data demonstrate that the systemic and mucosal immune systems are highly coordinated following vaccination...
  9. pmc Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer
    Kazutoyo Miura
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA
    Malar J 6:107. 2007
    ..A clear understanding of the relationship between antibody levels and TBA may allow ELISA determinations to be used to predict TBA and assist in planning vaccine development...
  10. ncbi Immunization with VP2 is sufficient for protection against lethal challenge with African horsesickness virus Type 4
    M A Stone-Marschat
    Molecular Pathology Unit, Plum Island Animal Disease Center, USDA, Greenport, New York 11944 0848, USA
    Virology 220:219-22. 1996
    ..These results demonstrate that AHSV VP2 alone is sufficient to induce a protective immune response in horses and indicate the usefulness of ELISA-reactive antibodies for differentiation of vaccinated and naturally exposed horses...
  11. pmc Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis
    Rhea N Coler
    Infectious Disease Research Institute, Seattle, Washington 98104, USA
    Infect Immun 70:4215-25. 2002
    ....
  12. ncbi Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans
    Samuel J McConkey
    Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, UK
    Nat Med 9:729-35. 2003
    ..Such heterologous prime-boost immunization approaches may provide a basis for preventative and therapeutic vaccination in humans...
  13. pmc A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV
    Clarisse Lorin
    Unite des Virus Lents, CNRS URA 1930, Institut Pasteur, Paris, France
    J Virol 78:146-57. 2004
    ..Therefore, recombinant MV vaccines inducing anti-HIV neutralizing antibodies and specific T lymphocytes responses deserve to be tested as a candidate AIDS vaccine...
  14. pmc Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier
    Z Q Xiang
    The Wistar Institute Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    J Virol 77:10780-9. 2003
    ..Oral priming-boosting regimens with either heterologous or homologous adenoviral vectors used sequentially increased both mucosal and systemic antibody titers to rabies virus [corrected]..
  15. ncbi Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans
    Helen McShane
    Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford, OX3 7LJ, UK
    Nat Med 10:1240-4. 2004
    ..Boosting vaccinations with MVA85A could offer a practical and efficient strategy for enhancing and prolonging antimycobacterial immunity in tuberculosis-endemic areas...
  16. ncbi An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants
    N F Rose
    Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA
    Cell 106:539-49. 2001
    ..Protection from AIDS was highly significant (p = 0.001). VSV vectors are promising candidates for human AIDS vaccine trials because they propagate to high titers and can be delivered without injection...
  17. pmc High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion
    Clemens H M Kocken
    Department of Parasitology, Biomedical Primate Research Centre, 2280 GH Rijswijk, The Netherlands
    Infect Immun 70:4471-6. 2002
    ..falciparum by immunofluorescence. In addition, purified immunoglobulin G from immunized animals strongly inhibited invasion of red blood cells by homologous and, to a somewhat lesser extent, heterologous P. falciparum...
  18. pmc A region of Plasmodium falciparum antigen Pfs25 that is the target of highly potent transmission-blocking antibodies
    A W Stowers
    Malaria Vaccine Development Unit, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 0425, USA
    Infect Immun 68:5530-8. 2000
    ..Vaccination strategies that target antibody response towards this domain may improve the efficacy of future transmission-blocking vaccines...
  19. ncbi A recombinant live attenuated measles vaccine vector primes effective HLA-A0201-restricted cytotoxic T lymphocytes and broadly neutralizing antibodies against HIV-1 conserved epitopes
    Clarisse Lorin
    Unite des Virus Lents, CNRS URA 1930, Institut Pasteur, 28 rue du Dr Roux, Paris 75015, France
    Vaccine 23:4463-72. 2005
    ..These results show that the MVSchw pediatric vaccination vector induces efficient cellular and humoral HIV-specific immune responses...
  20. ncbi Tuberculosis: vaccines in the pipeline
    Lan H Ly
    Department of Microbial and Molecular Pathogenesis, College of Medicine, Texas A and M University System Health Science Center, College Station, TX 77843 1114, USA
    Expert Rev Vaccines 7:635-50. 2008
    ..Some of these new vaccines may eventually be recommended for travelers to TB high-burden countries. This paper summarizes the progress of vaccine candidates in animal models to improve, replace or augment BCG vaccination...
  21. ncbi The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers
    Anna P Durbin
    Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
    Hum Vaccin 2:167-73. 2006
    ..These promising preclinical studies have identified rDEN1Delta30 as a candidate DEN1 vaccine virus for further testing in a human Phase I clinical trial...
  22. pmc Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25
    Joanna Kubler-Kielb
    Laboratory of Developmental and Molecular Immunity, National Institute of Child Health and Human Development, National Institutes of Health, 31 Center Drive, MSC 2423, Bethesda, MD 20892 2520, USA
    Proc Natl Acad Sci U S A 104:293-8. 2007
    ..The observed transmission-blocking activity of immune sera correlated with antibody levels measured by ELISA...
  23. ncbi Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2
    Krystyna Mozdzanowska
    Immunology Program, The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104 4268, USA
    Vaccine 21:2616-26. 2003
    ..Importantly, the protection in M2e-MAP- and infection-immunized mice appeared to be mediated by distinct immune mechanisms. This suggests that stronger protection may be achievable by combining both protective activities...
  24. pmc Attenuated Salmonella enterica serovar Typhi expressing urease effectively immunizes mice against Helicobacter pylori challenge as part of a heterologous mucosal priming-parenteral boosting vaccination regimen
    Patricia Londoño-Arcila
    Acambis Ltd, Cambridge, United Kingdom
    Infect Immun 70:5096-106. 2002
    ..The significance of these findings with regard to development of a human vaccine against H. pylori and modulation of immune responses by heterologous prime-boost immunization regimens is discussed...
  25. pmc Purification, characterization, and immunogenicity of a disulfide cross-linked Plasmodium vivax vaccine candidate antigen, merozoite surface protein 1, expressed in Escherichia coli
    S Dutta
    Department of Immunology, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910-7500, USA
    Infect Immun 69:5464-70. 2001
    ..These results indicate that PvMSP-1 p42 in combination with both of the adjuvants elicited cellular and humoral responses in mice...
  26. ncbi Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis
    Jun Wang
    Department of Pathology and Molecular Medicine and Division of Infectious Diseases, Centre for Gene Therapeutics, McMaster University, 1200 Main Street West, Hamilton, Ontario, Canada L8N 3Z5
    J Immunol 173:6357-65. 2004
    ..Our study also lends strong evidence that respiratory mucosal vaccination is critically advantageous over systemic routes of vaccination against TB...
  27. ncbi Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein
    Javier Mota
    Departamento de Arbovirus, Centro de Investigaciones sobre Enfermedades Infecciosas, Instituto Nacional de Salud Publica, Av Universidad No 655, Col Santa Maria Ahuacatitlan, CP 62508 Cuernavaca Morelos, Mexico
    Vaccine 23:3469-76. 2005
    ..Our results suggest that DIII can be used as a tetravalent DNA formulation to induce neutralizing and protective antibodies against dengue virus...
  28. ncbi A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major
    S Rafati
    Department of Immunology, Pasteur Institute of Iran, PO Box 11365 6699, Tehran, Iran
    Vaccine 19:3369-75. 2001
    ..This is the first report demonstrating that co-injection of two genes expressing different antigens induces a long lasting protective response, whereas the separate injection of cysteine proteases genes is not protective...
  29. ncbi Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis
    Azita Zadeh-Vakili
    Department of Immunology, Pasteur Institute of Iran, P O Box 11365 6699, Tehran, Iran
    Vaccine 22:1930-40. 2004
    ....
  30. ncbi Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato
    C O Tacket
    Center for Vaccine Development, Department of Medicine, University of Maryland School of Medicine, Baltimore 21201, USA
    Nat Med 4:607-9. 1998
    ..The present study was conducted as a proof of principle to determine if humans would also develop a serum and/or mucosal immune response to an antigen delivered in an uncooked foodstuff...
  31. ncbi Surface expression of an immunodominant malaria protein B cell epitope by yellow fever virus
    Myrna C Bonaldo
    Departamento de Bioquimica e Biologia Molecular, Fundação Oswaldo Cruz Instituto Oswaldo Cruz, Rio de Janeiro, RJ 21045 900, Brazil
    J Mol Biol 315:873-85. 2002
    ..The vectorial capacity of the yellow fever virus is being further explored for the expression and presentation of other epitopes, including those mediating T-cell responses...
  32. pmc Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2
    Joseph E Blaney
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 USA
    BMC Infect Dis 4:39. 2004
    ..To prepare a vaccine candidate, a previously described 30 nucleotide deletion (Delta30) in the 3' untranslated region of DEN-4 has been engineered into the DEN-2 isolate...
  33. ncbi Induction of neutralizing antibodies specific to dengue virus serotypes 2 and 4 by a bivalent antigen composed of linked envelope domains III of these two serotypes
    Saima Khanam
    International Centre for Genetic Engineering and Biotechnology, New Delhi, India
    Am J Trop Med Hyg 74:266-77. 2006
    ..This work could be a forerunner to the development of a single envelope domain III-based tetravalent antigen...
  34. ncbi Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21
    Oscar Kashala
    Aquila Biopharmaceuticals Inc, Framingham, MA 01702, USA
    Vaccine 20:2263-77. 2002
    ..These observations demonstrate that the use of QS-21 can substantially enhance the immunogenicity of peptide vaccines, such as SPf66...
  35. ncbi Progress towards an HIV vaccine based on recombinant bacillus Calmette-Guérin: failures and challenges
    Joan Joseph
    HIVACAT Catalan Center for HIV Vaccine Research and Development, AIDS Research Unit, Infectious Diseases Department, Hospital Clinic IDIBAPS, School of Medicine, University of Barcelona, Barcelona, Spain
    Expert Rev Vaccines 5:827-38. 2006
    ..Overcoming the remaining scientific, logistical and financial hurdles to the development of an effective HIV vaccine will require real imagination and firm commitment from all stakeholders...
  36. ncbi Priming of immune responses to hepatitis B surface antigen in young mice immunized in the presence of maternally derived antibodies
    R D Weeratna
    Coley Pharmaceutical Canada, 725 Parkdale Avenue, Ottawa ON, Canada K1Y 4E9
    FEMS Immunol Med Microbiol 30:241-7. 2001
    ..However, B cell responses to both HBsAg/alum/CpG ODN and DNA vaccines remained weak in the presence of maternally transferred anti-HBs antibodies...
  37. ncbi Expression of malaria transmission-blocking vaccine antigen Pfs25 in Pichia pastoris for use in human clinical trials
    Lanling Zou
    Malaria Vaccine Development Unit, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
    Vaccine 21:1650-7. 2003
    ..To address the low yield seen with S. cerevisiae, we also expressed Pfs25 in Pichia pastoris. P. pastoris is apparently superior to S. cerevisiae in producing higher yield, immunologically more potent, biologically more active Pfs25H-A...
  38. ncbi Plasmodium falciparum: immunogenicity of alum-adsorbed clinical-grade TBV25-28, a yeast-secreted malaria transmission-blocking vaccine candidate
    M M Gozar
    Malaria Vaccines Section, National Institutes of Health, Bethesda, Maryland 20892
    Exp Parasitol 97:61-9. 2001
    ..The apparent decrease in potency of clinical-grade TBV25-28 in rabbits appears to reflect an enhancement in potency of clinical-grade TBV25H in a new formulation rather than simply a species difference in immunogenicity of TBV25-28...
  39. ncbi Recombinant Semliki Forest virus vector exhibits potential for avian virus vaccine development
    K V Phenix
    Department of Veterinary Science, The Queen's University of Belfast, Stoney Road, Stormont, BT4 3SD, Northern Ireland, Belfast, UK
    Vaccine 19:3116-23. 2001
    ..Immunisation of 1-day-old SPF chicks with rSFV particles encoding the IBDV proteins resulted in specific antibodies being elicited in all birds, neutralising antibodies being induced in some but not all birds...
  40. ncbi Humoral and cellular immune responses in sheep immunized with a 22 kilodalton exported protein of Mycobacterium avium subspecies paratuberculosis
    Rachael C Rigden
    Institute of Veterinary, Animal and Biomedical Science, Massey University, Private Bag 11 222, Palmerston North, New Zealand
    J Med Microbiol 55:1735-40. 2006
    ..i. Recombinant P22 was able to stimulate significant IFN-gamma production in blood of P22-immunized sheep at 13 and 29 weeks p.i. Recombinant P22 also elicited an IFN-gamma response in blood of sheep immunized with Neoparasec...
  41. ncbi Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults
    Pierre Vandepapeliere
    GlaxoSmithKline Biologicals, 89 Rue de 1 institut, B 1330 Rixensart, Belgium
    Vaccine 23:2591-601. 2005
    ..AS02A can be considered as a useful adjuvant that strongly enhances the cellular and humoral responses of subunit protein vaccines...
  42. ncbi Recombinant fowlpox viruses coexpressing chicken type I IFN and Newcastle disease virus HN and F genes: influence of IFN on protective efficacy and humoral responses of chickens following in ovo or post-hatch administration of recombinant viruses
    K Karaca
    Department of Pathobiology, College of Veterinary Medicine, University of Minnesota, St Paul 55108, USA
    Vaccine 16:1496-503. 1998
    ..Chickens vaccinated with FPV coexpressing IFN and NDV genes produced less antibodies against NDV in comparison with chickens vaccinated with FPV expressing NDV genes...
  43. ncbi Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates
    M Hevey
    United States Army Medical Research Institute for Infectious Diseases, Fort Detrick, Frederick, Maryland, 21702, USA
    Virology 251:28-37. 1998
    ..Three monkeys vaccinated with replicons which expressed MBGV GP, and three others vaccinated with both replicons that expressed GP or NP, remained aviremic and were completely protected from disease...
  44. ncbi Development of recombinant VP2 vaccine for the prevention of infectious bursal disease of chickens
    Jun Rong
    Department of Biochemistry, College of Life Science, Wuhan University, Wuhan, Hubei 430072, PR China
    Vaccine 23:4844-51. 2005
    ..7% chickens. The results indicate that E. coli BL 21/pET 28 a-VP2 could be used to develop recombinant VP2 vaccine against infectious bursal disease in chickens...
  45. ncbi Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study
    Stephanie R Bialek
    Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Pediatr Infect Dis J 27:881-5. 2008
    ..Long-term follow-up studies of populations that received recombinant hepatitis B (HB) vaccination beginning at birth are limited...
  46. pmc A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins
    Peter J Bredenbeek
    Department of Medical Microbiology, Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands
    Virology 345:299-304. 2006
    ..This study demonstrates the potential to develop an YFV17D-based bivalent vaccine against two viruses that are endemic in the same area of Africa...
  47. ncbi Impact of vector-priming on the immunogenicity of a live recombinant Salmonella enterica serovar typhi Ty21a vaccine expressing urease A and B from Helicobacter pylori in human volunteers
    W G Metzger
    Max Planck Institut für Infektionsbiologie, Abteilung Molekulare Biologie, Schumannstrasse 21 22, D 10117 Berlin, Germany
    Vaccine 22:2273-7. 2004
    ..pylori urease (56%). This supports the results of a previous study in non-preimmunized volunteers where 56% (five of nine) of the volunteers showed a cellular immune response to urease after immunisation with S. typhi Ty21a (pDB1)...
  48. ncbi Introduction of mutations into the non-structural genes or 3' untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity
    Kathryn A Hanley
    Laboratory of Infectious Diseases LID, National Institute of Allergy and Infectious Diseases NIAID, National Institutes of Health NIH, Building 50, Room 6515, 50 South Drive, MSC 8007, Bethesda, MD 20892 8007, USA
    Vaccine 22:3440-8. 2004
    ..The application of these attenuating mutations to flavivirus vaccine development is discussed...
  49. ncbi Immunisation against plague by transcutaneous and intradermal application of subunit antigens
    J E Eyles
    Biomedical Sciences, Dstl, Porton Down, Salisbury, Wiltshire SP4 0JQ, UK
    Vaccine 22:4365-73. 2004
    ..These data suggest that transcutaneous immunisation may be a simple and non-invasive method for immunising individuals against plague...
  50. ncbi Structure-dependent efficacy of infectious bursal disease virus (IBDV) recombinant vaccines
    Jorge L Martinez-Torrecuadrada
    INGENASA, Hermanos Garci a Noblejas 41, 28037, Madrid, Spain
    Vaccine 21:3342-50. 2003
    ..Our results also provide clear evidence that the recombinant IBDV-derived antigens are structure-dependent in order to be efficient as vaccine components...
  51. ncbi Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity
    A C Stubbs
    Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado, USA
    Nat Med 7:625-9. 2001
    ..Recombinant yeast represent a novel vaccine strategy for the induction of broad-based cellular immune responses...
  52. ncbi Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein
    Suzanne L Epstein
    Laboratory of Immunology and Developmental Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Bethesda, MD 20852, USA
    Vaccine 23:5404-10. 2005
    ..Thus, gene-based vaccination with NP may contribute to protective immunity against diverse influenza viruses through its ability to stimulate cellular immunity...
  53. pmc The conformational restriction of synthetic vaccines for malaria
    A C Satterthwait
    Research Institute of Scripps Clinic, La Jolla, CA 92037
    Bull World Health Organ 68:17-25. 1990
    The effectiveness of synthetic vaccines is dependent upon the chance event that antibodies formed against largely disordered peptides can bind native protein surfaces which are often ordered...
  54. pmc Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding
    Eung Jun Im
    Weatherall Institute of Molecular Medicine, University of Oxford, The John Radcliffe, Oxford OX3 9DS, United Kingdom
    J Virol 81:9408-18. 2007
    ....
  55. ncbi Synthetic vaccines: the role of adjuvants in immune targeting
    Zi Hua Jiang
    Biomira Inc, 2011 94 Street, Edmonton, Alberta, T6N 1H1, Canada
    Curr Med Chem 10:1423-39. 2003
    ..b>Synthetic vaccines containing specific epitopes to which immune responses are desired, are expected to be far superior in ..
  56. ncbi Recombinant Salmonella vaccines for biodefence
    Helen S Atkins
    Defence Science and Technology Laboratory, Porton Down, Salisbury SP4 0JQ, UK
    Vaccine 24:2710-7. 2006
    ..In this review, the technologies used, considerations needed, progress made, and future prospects for developing multivalent Salmonella-based vaccines for biodefence are discussed...
  57. pmc An IgG1 titre to the F1 and V antigens correlates with protection against plague in the mouse model
    E D Williamson
    DERA, Chemical and Biological Defence Sector, Salisbury, UK
    Clin Exp Immunol 116:107-14. 1999
    ..05) with protection. The titres of IgG1 in vaccinated mice which correlated with 90%, 50% and 10% protection have been determined and provide a useful model to predict vaccine efficacy in man...
  58. ncbi Enhancing immunogenicity and reducing dose of microparticulated synthetic vaccines: single intradermal administration
    Angel M Carcaboso
    Pharmacy and Pharmaceutical Technology Laboratory, Faculty of Pharmacy, University of the Basque Country UPV EHU, Paseo de la Universidad no 7, 01006 Vitoria Gasteiz, Spain
    Pharm Res 21:121-6. 2004
    ..Our purpose was to evaluate the ability of a polymeric vehicle to release a model synthetic vaccine to the skin in order to reach a potent activation of the specific immune response...
  59. ncbi Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant
    Yasir A W Skeiky
    Corixa Corporation, 1124 Columbia Street, Suite 200, Seattle, WA 98104, USA
    Vaccine 20:3292-303. 2002
    ....
  60. ncbi rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers
    Anna P Durbin
    Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205, USA
    J Infect Dis 191:710-8. 2005
    ..The live attenuated dengue virus type 4 (DEN-4) vaccine candidate virus rDEN4 Delta 30 was previously found to be safe and immunogenic at a dose of 10(5) plaque-forming units (pfu)...
  61. ncbi Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines
    William A Ernst
    Molecular Express, Inc 13310 S Figueroa Street, Los Angeles, CA 90061, USA
    Vaccine 24:5158-68. 2006
    ....
  62. ncbi Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity
    John W Shiver
    Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    Nature 415:331-5. 2002
    ..The replication-defective adenovirus is a promising vaccine vector for development of an HIV-1 vaccine...
  63. pmc Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector
    Andrew T Catanzaro
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 3017, USA
    J Infect Dis 194:1638-49. 2006
    ..Here, we report the safety, tolerability, and immunogenicity of a replication-defective recombinant adenovirus serotype 5 (rAd5) vector HIV-1 candidate vaccine...
  64. ncbi Mechanisms of mucosal and parenteral tuberculosis vaccinations: adenoviral-based mucosal immunization preferentially elicits sustained accumulation of immune protective CD4 and CD8 T cells within the airway lumen
    Michael Santosuosso
    Department of Pathology and Molecular Medicine and Division of Infectious Diseases, Center for Gene Therapeutics, McMaster University, Hamilton, Ontario, Canada
    J Immunol 174:7986-94. 2005
    ....
  65. ncbi Genetically modified, live attenuated dengue virus type 3 vaccine candidates
    Joseph E Blaney
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 8007, USA
    Am J Trop Med Hyg 71:811-21. 2004
    ..Thus, the rDEN3/4(ME) and rDEN3/4Delta30(ME) antigenic chimeric viruses can be considered for evaluation in humans and for inclusion in a tetravalent dengue vaccine...
  66. pmc Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria
    Elissa M Malkin
    Johns Hopkins University Bloomberg School of Public Health, Center for Immunization Research, 624 N Broadway, Room 217, Baltimore, MD 21205, USA
    Infect Immun 73:3677-85. 2005
    ..To our knowledge, this is the first AMA1 vaccine candidate to elicit functional immune responses in malaria-naive humans, and our results support the further development of this vaccine...
  67. ncbi Immunization with recombinant modified vaccinia Ankara (rMVA) constructs encoding the HA or NP gene protects ponies from equine influenza virus challenge
    C C Breathnach
    Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706, USA
    Vaccine 24:1180-90. 2006
    ....
  68. pmc Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development
    Claire Y H Huang
    Division of Vector Borne Infectious Diseases, Centers for Disease Control and Prevention, Public Health Service, U S Department of Health and Human Services, Fort Collins, Colorado 80522, USA
    J Virol 77:11436-47. 2003
    ..The results of this study demonstrate that the unique attenuation loci of D2 PDK-53 virus make it an attractive vector for the development of live attenuated flavivirus vaccines...
  69. pmc Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria
    Anthony W Stowers
    Malaria Vaccine Development Unit, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland 20852, USA
    Infect Immun 70:6961-7. 2002
    ..The protection induced by a combination vaccine of AMA1 and MSP1 was not superior to the protection obtained with AMA1 alone, although the immunity generated appeared to operate against both vaccine components...
  70. pmc Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes
    Giovanna Barba-Spaeth
    Laboratory of Virology and Infectious Disease, Center for the Study of Hepatitis C, The Rockefeller University, New York, NY 10021, USA
    J Exp Med 202:1179-84. 2005
    ..These findings offer insight into the immunologic mechanisms associated with the highly capable YF17D vaccine that may guide effective vaccine design...
  71. ncbi Factors influencing the immune response to foreign antigen expressed in recombinant BCG vaccines
    Maureen Dennehy
    The Biovac Institute, Private Bag X3, Pinelands, 7430 Cape Town, South Africa
    Vaccine 23:1209-24. 2005
    ..Genetic and functional stability of rBCG is reviewed in the second section. In the last section, the influence of dose and route of immunization, strain of BCG and the animal model used are discussed...
  72. pmc Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6
    A Weinrich Olsen
    Department of TB Immunology, Statens Serum Institute, Copenhagen, Denmark
    Infect Immun 69:2773-8. 2001
    ..The vaccine induced efficient immunological memory, which remained stable 30 weeks postvaccination...
  73. ncbi Effect of the malaria vaccine Combination B on merozoite surface antigen 2 diversity
    Christian Flück
    Swiss Tropical Institute, Socinstrasse 57, Postfach, CH 4002 Basel, Switzerland
    Infect Genet Evol 7:44-51. 2007
    ....
  74. ncbi Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers
    Shelly A McNeil
    Clinical Trials Research Center, IWK Health Centre, Dalhousie University, Halifax, Nova Scotia, Canada
    Clin Infect Dis 41:1114-22. 2005
    ..New molecular techniques have allowed the previous obstacles to be largely overcome...
  75. pmc Immune responses to recombinant pneumococcal PspA antigen delivered by live attenuated Salmonella enterica serovar typhimurium vaccine
    Ho Young Kang
    Department of Biology, Washington University, St Louis, Missouri 63130, USA
    Infect Immun 70:1739-49. 2002
    ..Oral immunization with Salmonella-PspA vaccine protected 60% of immunized mice from death after intraperitoneal challenge with 50 times the 50% lethal dose of virulent S. pneumoniae WU2...
  76. ncbi Recent progress in the development of plant derived vaccines
    Vidadi Yusibov
    Fraunhofer USA Center for Molecular Biotechnology, 9 Innovation Way, Suite 200, Newark, DE 1971, USA
    Expert Rev Vaccines 7:1173-83. 2008
    ..The particular advantages of plant-based vaccines in terms of cost, safety and scalability are discussed in the light of recent successful clinical trials and the likely impact of plant systems on the vaccine industry is evaluated...
  77. ncbi Immunization against Plasmodium chabaudi malaria using combined formulations of apical membrane antigen-1 and merozoite surface protein-1
    James M Burns
    Department of Microbiology and Immunology, Drexel University College of Medicine, 2900 Queen Lane, Philadelphia, PA 19129, USA
    Vaccine 21:1843-52. 2003
    ....
  78. ncbi Avian adenovirus CELO recombinants expressing VP2 of infectious bursal disease virus induce protection against bursal disease in chickens
    Achille Francois
    Agence Francaise de Securite Sanitaire des Aliments, Molecular Biology Unit, Zoopole les Croix, B P 53, Ploufragan 22440, France
    Vaccine 22:2351-60. 2004
    ..These results indicate that CELO-based vectors are useful to safely induce a strong protective immunity against vvIBDV in chickens...
  79. ncbi Orally delivered foot-and-mouth disease virus capsid protomer vaccine displayed on T4 bacteriophage surface: 100% protection from potency challenge in mice
    Z J Ren
    Expression BioSciences Inc, Somerset, NJ 08873, USA
    Vaccine 26:1471-81. 2008
    ..This study represents a clear example of how FMD and other pathogenic disease vaccines can be prepared by a simple and efficient bacteriophage route...
  80. pmc Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis
    G W Anderson
    United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21702 5011, USA
    Infect Immun 64:4580-5. 1996
    ..pestis...
  81. ncbi Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region
    A P Durbin
    Center for Immunization Research, Johns Hopkins School of Public Health, Baltimore, Maryland 21205, USA
    Am J Trop Med Hyg 65:405-13. 2001
    ..The low level of reactogenicity and high degree of immunogenicity of this vaccine candidate warrant its further evaluation and its use to create chimeric vaccine viruses expressing the structural genes of dengue virus types 1, 2, and 3...
  82. ncbi Antibody response of naturally infected individuals to recombinant Plasmodium vivax apical membrane antigen-1
    Maria Helena C Rodrigues
    Departamento de Analises Clinicas e Toxicologicas, Faculdade de Ciencias Farmaceuticas, Universidade de Sao Paulo, Av Prof Lineu Prestes, 580, Cidade Universitaria, São Paulo SP 05508 900, Brazil
    Int J Parasitol 35:185-92. 2005
    ..Based on these observations, we conclude that PvAMA-1 merits further immunological studies as a vaccine candidate against P. vivax malaria...
  83. ncbi Construction and evaluation of a multistage combination vaccine against malaria
    Qingfeng Zhang
    Department of Etiologic Biology and State Key Laboratory of Medical Immunology, Second Military Medical University, 800 Xiang Yin Road, Shanghai 200433, China
    Vaccine 25:2112-9. 2007
    ..Rabbits antisera to combination antigens strongly inhibited blood-stage parasite growth in vitro. These results suggest that the recombinant antigens are potential candidates for multistage combination vaccines against malarial parasite...
  84. ncbi A phase 1 trial of PfCP2.9: an AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria
    Elissa Malkin
    PATH Malaria Vaccine Initiative, Bethesda, MD, USA
    Vaccine 26:6864-73. 2008
    ..At all three dose levels and both schedules, this formulation of PfCP2.9/ISA 720 is well tolerated, safe and immunogenic; however no functional activity against the parasite was observed...
  85. ncbi Induction of MUC1-specific cellular immunity by a recombinant BCG expressing human MUC1 and secreting IL2
    Jianbo He
    Revlon UCLA Breast Center, Department of Surgery, University of California at Los Angeles, School of Medicine, 90095, USA
    Int J Oncol 20:1305-11. 2002
    ..These results suggest that BCG-MUC1-IL2 preferentially induces MUC1-specific cellular immune responses and it may serve as a vaccine for breast cancer prevention and treatment...
  86. pmc Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys
    Joseph E Blaney
    Laboratory of Infectious Diseases, NIH, NIAID, LID Twinbrook III, Room 3W 13, 12735 Twinbrook Parkway, MSC 8133, Bethesda, MD 20892 8133, USA
    J Virol 79:5516-28. 2005
    ..However, two doses of TV-2 or TV-3 induced protection against DEN2 challenge. Two tetravalent formulations, TV-2 and TV-3, possess properties of a successful DEN vaccine and can be considered for evaluation in clinical trials...
  87. ncbi Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein
    Yasir A W Skeiky
    Corixa Corp, Seattle, WA 98104, USA
    J Immunol 172:7618-28. 2004
    ..tuberculosis comparable to bacillus Calmette-Guérin immunization. Mtb72F in AS02A formulation is currently in phase I clinical trial, making it the first recombinant tuberculosis vaccine to be tested in humans...
  88. ncbi Recombinant fowlpox viruses inducing protective immunity against Newcastle disease and fowlpox viruses
    R Ogawa
    Biological Science Institute, R and D Center, Nippon Zeon Co Ltd, Kawasaki, Japan
    Vaccine 8:486-90. 1990
    ..5 kDa polypeptide gene promoter. Immunization with the recombinant fowlpox virus elicited protective immunity in chickens against both virulent Newcastle disease and fowlpox virus infection...
  89. ncbi Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates
    F Guirakhoo
    Acambis Inc, Cambridge, Massachusetts 02139, USA
    Virology 298:146-59. 2002
    ..This indicates that further formulations for dose adjustments need to be tested in monkeys to identify an optimal formulation for humans...
  90. pmc Cellular immunity induced by the recombinant Plasmodium falciparum malaria vaccine, RTS,S/AS02, in semi-immune adults in The Gambia
    M Pinder
    Medical Research Council Laboratories, Banjul, The Gambia
    Clin Exp Immunol 135:286-93. 2004
    ..We have therefore identified several peptide-specific T cell responses induced by RTS,S/AS02 which provides a mechanism to investigate potentially protective immune responses in the field...
  91. ncbi Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up study at 15 years
    Laura L Hammitt
    Arctic Investigations Program, Centers for Disease Control and Prevention, Anchorage, AK, USA
    Vaccine 25:6958-64. 2007
    ..These children had protective anti-HBs concentrations when tested after receiving a three-dose series of 2.5 microg recombinant hepatitis B vaccine starting at birth...
  92. ncbi Vaccination trials in Australia and Argentina confirm the effectiveness of the EG95 hydatid vaccine in sheep
    M W Lightowlers
    Molecular Parasitology Laboratory, The University of Melbourne, VIC Australia
    Int J Parasitol 29:531-4. 1999
    ..Vaccination reduced the number of viable cysts by 99.3% compared with unvaccinated controls. These results suggest that the EG95 vaccine could have wide applicability as a new tool for use in hydatid control campaigns...
  93. ncbi A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant
    Scott A Halperin
    Department of Pediatrics, Clinical Trials Research Center, Dalhousie University, IWK Health Centre, 5850 University Avenue, Halifax, NS, Canada B3J 3G9
    Vaccine 21:2461-7. 2003
    ....
  94. ncbi Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles
    P V Lalitha
    School of Life Sciences, Jawaharlal Nehru University, New Delhi 110067, India
    Vaccine 26:4526-35. 2008
    ....
  95. ncbi Vaccination with recombinant tick antigens for the control of Ixodes scapularis adult infestations
    Consuelo Almazan
    Department of Veterinary Pathobiology, Center for Veterinary Health Sciences, 250 McElroy Hall, Oklahoma State University, Stillwater, OK 74078, USA
    Vaccine 23:5294-8. 2005
    ..These antigens, and especially 4D8, appear to be good candidates for continued development of a vaccine for control of tick infestations...
  96. ncbi Vaccination against cestode parasites: anti-helminth vaccines that work and why
    M W Lightowlers
    The University of Melbourne, Veterinary Clinical Centre, VIC 3030, Werribee, Australia
    Vet Parasitol 115:83-123. 2003
    ..The high level of efficacy of the vaccines against T. solium cysticercosis and hydatid disease suggests that they would be effective also if used directly in humans...
  97. ncbi Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis
    CHING JUH LAI
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Adv Virus Res 61:469-509. 2003
    ..The chimeric flavivirus strategy has led to the rapid development of novel live-attenuated vaccines against dengue, TBE, JE, and West Nile viruses...
  98. pmc Expression and immunogenicity of an Echinococcus granulosus fatty acid-binding protein in live attenuated Salmonella vaccine strains
    J A Chabalgoity
    Department of Microbiology, The Medical School, University of Newcastle, Newcastle upon Tyne, United Kingdom
    Infect Immun 65:2402-12. 1997
    ..Salmonellae expressing the TetC-rEgDfl fusion are currently under evaluation as potential vaccines against E. granulosus...
  99. ncbi Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid
    W A Keitel
    Department of Microbiology and Immunology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Vaccine 18:531-9. 1999
    ..Both MSP-1(19) vaccines were immunogenic in humans, but changes in formulation will be necessary to improve safety and immunogenicity profiles...
  100. ncbi Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis
    Ricardo Toshio Fujiwara
    Laboratório de Leishmanioses e Vacinas, Departamento de Parasitologia, Instituto de Ciencias Biologicas, Universidade Federal de Minas Gerais UFMG, CEP 31270 901, Belo Horizonte, MG, Brazil
    Vet Res 36:827-38. 2005
    ..These results point to the possible use of this antigen cocktail formulated with the adjuvant MPL-SE in efficacy field trials against canine VL...
  101. ncbi Antigen cocktails: valid hypothesis or unsubstantiated hope?
    Peter Willadsen
    CSIRO Livestock Industries, Queensland Bioscience Precinct, 306 Carmody Road, St Lucia, Queensland 4067, Australia
    Trends Parasitol 24:164-7. 2008
    ..The experimental evidence for it, however, is extremely scarce and contradictory. The efficacy of multicomponent vaccines deserves greater experimental attention than it has received...

Research Grants62

  1. Experimental Molecular Vaccines for Schistosomiasis
    Afzal A Siddiqui; Fiscal Year: 2012
    ..Such a vaccine would greatly reduce the need for logistically difficult and expensive drug-based programs and will save millions of lives. ..
  2. Synthesis of immunogenic glycolipopeptides for the development of vaccines for Ch
    Katja Michael; Fiscal Year: 2010
    ..for Chagas disease by the idea of incorporating parasitic cell surface carbohydrate epitopes into fully synthetic vaccines. The glycocalix of trypomastigotes, the infective forms of the parasite, contains large amounts of ..
  3. A fully synthetic carbohydrate-based cancer vaccine
    Geert Jan Boons; Fiscal Year: 2013
    ..We are developing fully synthetic multi-component vaccine candidates that can overcome the poor immunogenicity of tumor-associated carbohydrates and offer a prospect for use in cancer immune therapy. ..
  4. PHYSIOLOGICAL CHEMISTRY OF INTEGRIN FUNCTION
    MICHAEL LORAN DUSTIN; Fiscal Year: 2010
    ..stability through manipulation of LFA-1 molecular and supramolecular chemistry have potential applications in treatment of autoimmune disease and allergy and the development of synthetic vaccines with improved efficacy.
  5. Synthetic Ligands for Modulating B-Cell Responses
    Laura L Kiessling; Fiscal Year: 2013
    ..We anticipate that the proposed investigations can give rise to new chemical biology strategies for eliciting immunity or tolerance. ..
  6. UC Davis/NIH NeuroMab Facility
    James S Trimmer; Fiscal Year: 2013
    ..Moreover, NeuroMabs will continue to find additional applications in direct functional analyses of proteins, in diagnostic procedures, and as therapeutics. ..
  7. Molecular Recognition in Dendrimers Based on Melamine
    Eric Simanek; Fiscal Year: 2009
    ..Specific Aim #3: Explore macromolecular recognition to determine the molecular parameters that allow these dendrimers to serve as synthetic vaccines and as multi-functional adaptor units on antibodies.
  8. SBIR TOPIC 255
    PETER M PUSHKO; Fiscal Year: 2009
    ..Immunogenicity, safety, and feasibility of synthetic vaccines will be evaluated.
  9. CARHOHYDRATE MOIETIES OF GP120
    Khushi Matta; Fiscal Year: 1993
    ..The effect of glycosylation inhibitors on gp120 maturation will be assessed in a variety of transfected cell lines and in virus-infected cells. Our potential inhibitors may prove to be chemotherapeutic agents for AIDS...
  10. T CELL IMMUNITY AND SYNTHETIC PEPTIDE AIDS VACCINES
    Amnon Altman; Fiscal Year: 1991
    ..The proposed studies could constitute a step towards the formulation of effective and highly immunogenic synthetic vaccines against AIDS and other infectious diseases.
  11. BIOMEDICAL RESEARCH SUPPORT GRANT
    Hyman Hops; Fiscal Year: 1991
    ..Dr. Mannino (AI-28171-01) needs a sensitive sequencer for his work on AIDS- related antigens in design of synthetic vaccines. Dr...
  12. DEVELOPMENT OF A SYNTHETIC VACCINE TO RETROVIRUSES
    John Elder; Fiscal Year: 1990
    ..These studies should yield an accurate assessment of the practicality of synthetic vaccines against a family of retroviruses...
  13. TRAP AS A CANDIDATE MALARIA VACCINE
    Victor Nussenzweig; Fiscal Year: 2000
    ..4) to develop synthetic vaccines that elicit specific antibodies against surface-exposed loops presumably located at the edges of the MIDAS ..
  14. SBIR TOPIC 255, PHASE II: SYNTHETIC VACCINES AGAINST PROSTATE CANCER
    Peter Pushko; Fiscal Year: 2011
    ..The latter represent non-replicating virus-like particles configured to encapsidate expression vector for in vivo delivery and expression of engineered PSA genes. ..
  15. Human Monoclonal Antitoxin to Anthrax Protective Antigen
    Susan Zolla Pazner; Fiscal Year: 2003
    ..Protective functions will be assessed in vitro by measuring the ability of individual mAbs or combinations of mAbs to block the lethal effects of anthrax toxin. ..
  16. CRYSTALLOGRAPHIC STUDIES ANTIBODY-ANTIGEN RECOGNITION
    Ian Wilson; Fiscal Year: 1993
    ..In both these systems crystals of both the free Fab and Fab-antigen complex are available and hence one can evaluate for the first time whether any changes in antibody structure accompany antigen binding...
  17. SYNTHETIC MONOSACCHARIDES ADJUVANTS FOR HUMAN VACCINES
    David Johnson; Fiscal Year: 2000
    ..can potentially l) improve the safety and efficacy of existing infectious disease and cancer vaccines, and 2) lead to the development of new wholly synthetic vaccines comprising synthetic adjuvants and antigens.
  18. IMMUNE MECHANISMS IN HALOTHANE HEPATITIS
    A Gandolfi; Fiscal Year: 1992
    ..These studies will determine if a hypersensitivity immune response is instrumental in the pathogenic mechanisms of drug/anesthetic induced liver damage...
  19. GENE-MODIFIED DENDRITIC CELLS FOR TUMOR IMMUNOTHERAPY
    Saswati Chatterjee; Fiscal Year: 1999
    ....
  20. NOVEL AMPHIPATHIC ALDEHYDES AS ADJUVANTS FOR VACCINES
    David Johnson; Fiscal Year: 2000
    ..can potentially improve the safety and efficacy of both existing infectious disease vaccines and emerging synthetic vaccines. The anticipated high aqueous solubility and stability of these adjuvants should also facilitate vaccine ..
  21. Multivalent gp41 Peptides as Novel Immunogens
    Lai Xi Wang; Fiscal Year: 2004
    ..The structure-immunogenicity relationships will be evaluated. It is expected that the proposed studies will yield important new data with significant relevance to the development of an effective HIV-1 vaccine. ..
  22. ANTIBODIES TO VINYL METABOLITES IN CARCINOGENESIS STUDY
    John Wong; Fiscal Year: 1990
    ..In summary, this grant will support the production of 4 MAb and laboratory evaluation of their applicability in vinyl carcinogenesis study...
  23. SYNTHETIC HEPATITIS C ANTIGENS FOR SUBUNIT VACCINE
    ALAN WALFIELD; Fiscal Year: 1991
    ..A vaccine for hepatitis C would be the final application of this research proposal. Biologicals for the treatment of HCV infection may also be generated by this project...
  24. HIV-1 Glycopeptides as Immunogens
    Lai Xi Wang; Fiscal Year: 2009
    ..Theproposed research attempts to raise broadly neutralizing antibodies through novel immunogen design. Theresearch willyield important new data with direct relevance to HIV-1 vaccine development. ..
  25. Structure-Based Design of Drugs and Vaccines for Target*
    Edward Arnold; Fiscal Year: 2006
    ..Project 4 (Roger Jones; Rutgers) will synthesize oligonucleotides that are tailored for structural and mechanistic studies (with Projects 2, 3, and 4) and dinucleoside tetraphosphates as potential RT inhibitors. ..
  26. INFLUENCE OF IMMUNIZATION REGIMEN ON HELPER T CELLS
    Barbara Fox; Fiscal Year: 1992
    The rational design of synthetic vaccines would be greatly facilitated by the ability to modulate the specificity, avidity or phenotype of the elicited helper T cells...
  27. IMMUNE RESPONSE TO CLONED SCHISTOSOME ANTIGENS
    JOHN CORDINGLEY; Fiscal Year: 1992
    ..Further schistosome antigen clones relevant to immunity will be sought by a number of approaches. Suitable synthetic and recombinant antigens will be tested for their ability to induce immunity in experimental animals...
  28. PROTECTIVE IMMUNITY TO HUMAN IMMUNODEFICIENCY VIRUS
    Edward Mocarski; Fiscal Year: 1990
    ..out in the RFA: (i) whole HIV vaccine, (ii) subunit vaccine, (iii) recombinant DNA produced antigens, (iv) synthetic vaccines, and (v) use of viral vectors. Project I (Dr...
  29. Trypanosoma cruzi Mucosal/Systemic Protective Immunity
    DANIEL HOFT; Fiscal Year: 2003
    ..Chemokine and/or integrin receptor expression will be studied by flow cytometry and RT-Real-Time PCR, and the in vivo effects of defective chemokine and integrin binding and/or signaling will be evaluated. ..
  30. MOLECULAR PROBES OF MYOSIN STRUCTURE AND INTERACTIONS
    DONALD WINKELMANN; Fiscal Year: 1991
    ..This may yield valuable insights into the structure of antigenic regions on proteins which will aid in the prediction of immunogenicity for design of synthetic vaccines.
  31. Identification of SARS Antigens for Serodiagnosis
    Andrew Levin; Fiscal Year: 2005
    ..4) Generation of monoclonal and polyclonal antibodies to specific SARS antigens, for use in antigen capture assays. ..
  32. FAE specific receptors for targeted vaccine delivery
    David Lo; Fiscal Year: 2004
    ..The development of successful targeting ligands would comprise a novel platform for the development of synthetic vaccines, especially for the induction of mucosal immunity against agents such as influenza.
  33. PEPTIDE SYNTHETIC AND ANALYTICAL WORKSTATION
    Laszlo Otvos; Fiscal Year: 1991
    ..problems as chemical and conformational requirements for T-cell epitopic regions of proteins, development of synthetic vaccines and identification of abnormally processed protein structures that are involved in the formation of senile ..
  34. VACCINE DEVELOPMENT FOR IMMUNODEFICIENCY VIRUSES
    James Young; Fiscal Year: 1993
    ..We believe that such a strategy will markedly increase the chances to develop and use a multivalent, broadly protective vaccine against Human Immunodeficiency Viruses...
  35. 3-D STRUCTURES OF VIRAL ANTIGEN-ANTIBODY COMPLEXES
    Peter Colman; Fiscal Year: 1990
    ..antigenic variation in this and other variable viruses (such as HIV), (c) help to provide a general understanding of immune recognition, at least as regards B cell immunity, and (d) aid in the future rational design of synthetic vaccines.
  36. VACCINATION AGAINST S. MANSONI WITH PURIFIED ANTIGENS
    Donald Harn; Fiscal Year: 1990
    ..Assays for sensitization to antigens will be done by both lung and liver granuloma assays...
  37. SYNTHETIC IGE VACCINE FOR THE TREATMENT OF ALLERGY
    ALAN WALFIELD; Fiscal Year: 1992
    ..The peptide-carrier configuration that elicits the most active anti-sera will be selected for further research and development...
  38. HUMAN FETAL NEUROENDOCRINOLOGY
    SHIRLEY JOSEPH; Fiscal Year: 1980
    ..We will continue these studies in a correlative way by comparing radioimmunoassay and bioassay (wherever possible) in discrete regions of fetal and newborn brain...
  39. CD4 BINDING SITE ON HIV1 GP120 AS A VACCINE ANTIGEN
    Martin Teintze; Fiscal Year: 2000
    ....
  40. A TB Vaccine for AIDS Patients
    MARCUS AARON HORWITZ; Fiscal Year: 2010
    ..Finally, we shall confirm the safety of the new recombinant vaccines in an immunocompromised animal host (SCID mouse model). ..
  41. DEVELOPMENT AND TESTING OF NEW TUBERCULOSIS VACCINES
    MARCUS AARON HORWITZ; Fiscal Year: 2010
    ..tuberculosis. Lay Summary: Tuberculosis is a major worldwide public health problem. This proposal seeks to develop a more potent vaccine with which to combat this disease. ..
  42. Novel Antimicrobial Agents Against M. tuberculosis
    MARCUS HORWITZ; Fiscal Year: 2008
    ..mammalian GS, and test the toxicity of the analogs in mice. 2) Test the novel MSO analogs for their capacity to inhibit M. tuberculosis growth in broth culture, in human macrophages, and in guinea pigs. ..
  43. M TUBERCULOSIS GLUTAMINE SYNTHETASE EXPORT & INHIBITION
    MARCUS HORWITZ; Fiscal Year: 2002
    ..tuberculosis glutamine synthetase, they hope to develop more active entities than the parent compound and thereby to develop a new antibiotic against M. tuberculosis. ..
  44. Characterization of the Francisella tularensis phagosome
    MARCUS HORWITZ; Fiscal Year: 2003
    ..tularensis subverts the host cell membrane trafficking pathways and attains an intracellular compartment that is hospitable for its survival and growth will help guide new strategies for the prevention and treatment of tularemia. ..
  45. Characterization of the M. tuberculosis phagosome
    MARCUS HORWITZ; Fiscal Year: 2007
    ..These experiments will advance our understanding of the cell biology and pathogenic mechanisms of M. tuberculosis and facilitate the development of new strategies to combat tuberculosis. [unreadable] [unreadable]..
  46. M TUBERCULOSIS PHAGOSOME
    MARCUS HORWITZ; Fiscal Year: 2002
    ..tuberculosis to survive and multiply within its host cells and should facilitate the development of new strategies for prevention and treatment of tuberculosis. ..
  47. IMMUNOREGULATION IN AIDS
    Norman Letvin; Fiscal Year: 2008
    ..3. Nondominant SHIV epitope-specific CTL populations. A. Breadth and magnitude. B. Functional repertoire. C. TCR repertoire. 4. Nondominant epitope-specific CTL and control of SIV replication. [unreadable] [unreadable]..
  48. HOOKWORM LARVAL INFECTIVITY AND DEVELOPMENT
    Peter Hotez; Fiscal Year: 2002
    ..The pharmacologic manipulation of parasite-derived protein kinases may offer a new approach to chemotherapy by taking larvae out of arrest. ..
  49. DNA VACCINE IMMUNITY TO HIV1 AND SIV
    Norman Letvin; Fiscal Year: 2002
    ..This aim therefore studies cross reactivity to a single epitope not multi epitopes. ..
  50. Conference HIV Vaccine Development Progress & Prospects
    Norman Letvin; Fiscal Year: 2004
    ..abstract_text> ..
  51. Chimeric Adenovirus Vaccine Vectors for HIV/SIV
    DAN BAROUCH; Fiscal Year: 2005
    ..Within the two-year time frame of this award, sufficient data will be generated with candidate chimeric rAd vaccines to justify further vaccine/challenge studies in rhesus monkeys. ..
  52. Cytokine-Augmented DNA Vaccine-Elicited Immunity to HIV
    DAN BAROUCH; Fiscal Year: 2005
    ..Raphael Dolin, Dean for Clinical Programs, Harvard Medical School, will guide Dr. Barouch's development as an independent investigator. In addition, a committee of distinguished scientists will oversee his progress toward independence. ..
  53. Augmentation of DNA Vaccine-Elicited Immunity to HIV/SIV
    DAN BAROUCH; Fiscal Year: 2008
    ..The long-term objectives of these studies are to develop novel vaccine regimens that recruit APCs to the site of inoculation in animal models and to consider advancing the most promising strategies into clinical trials. ..
  54. Novel Adenovirus Vaccine Vectors for HIV/SIV
    Dan H Barouch; Fiscal Year: 2010
    ..abstract_text> ..
  55. Chronic Tuberculosis: Latent or Dynamic
    Ian Orme; Fiscal Year: 2008
    ..unreadable] [unreadable]..
  56. Adrenergic Antagonism During Murine Candidiasis
    Brad Spellberg; Fiscal Year: 2008
    ..For these reasons, the potential for adrenergic antagonism to act as an effective immunotherapy is highly meritorious of investigation in this training application. ..
  57. ALABAMA/ZAMBIA HIV VACCINE CLINICAL TRIALS UNIT (HVTU)
    Paul Goepfert; Fiscal Year: 2006
    ..Recently, the Alabama clinic enrolled 125 higher-risk gay men in <5 months in the first US phase III trial. Plans for utilizing these cohorts and others are described. ..
  58. STRATEGIES FOR TUBERCULOSIS VACCINE DEVELOPMENT AND SCRE
    Ian Orme; Fiscal Year: 2004
    ..abstract_text> ..
  59. Innate Effectors of rAls3p-N Anti-Candida Vaccine
    Brad J Spellberg; Fiscal Year: 2010
    ..PNS 398/2590 (Rev. 11/07) Page - Continuation Format Page ..
  60. CD8+ T cell cytokine production in HIV-1 infection
    Paul Goepfert; Fiscal Year: 2005
    ..An HIV-1 vaccine would also be enhanced by identifying CD8+ T cell epitopes that portend a favorable prognosis and are difficult for the virus to mutate (specific aims 2 and 3). ..
  61. Characterization of a vaccine against Chlamydia trachomatis
    RHEA COLER; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..